Alterola Biotech (ABTI) 10-Q 8 May 15 2015 Q2 Quarterly report Financial data

Document_and_Entity_Informatio

Document and Entity Information	6 Months Ended
	Mar. 31, 2015	Apr. 23, 2015
Document And Entity Information
Entity Registrant Name	ALTEROLA BIOTECH INC.
Entity Central Index Key	1442999
Document Type	10-Q
Document Period End Date	31-Mar-15
Amendment Flag	FALSE
Current Fiscal Year End Date	-21
Is Entity a Well-known Seasoned Issuer?	No
Is Entity a Voluntary Filer?	No
Is Entity's Reporting Status Current?	Yes
Entity Filer Category	Smaller Reporting Company
Entity Common Stock, Shares Outstanding		114,980,000
Document Fiscal Period Focus	Q2
Document Fiscal Year Focus	2015

Balance_Sheets

Balance Sheets (USD $)	Mar. 31, 2015	Sep. 30, 2014
Current Assets
Cash and equivalents	$9,156
Prepaid expenses
Deferred financing costs
Total current assets	9,156
Website net	6,200	6,200
TOTAL ASSETS	15,356	6,200
Current Liabilities
Accrued expenses	31,634	35,008
Accrued interest	53,509	45,784
Advances for director	750	750
Notes payable	150,000	130,000
Total Liabilities	235,893	211,542
Stockholders Deficit
Preferred Stock, $.001 par value, 10,000,000 shares authorized, -0- shares issued and outstanding
Common Stock, $.001 par value, 140,000,000 shares authorized,114,980,000 shares issued and outstanding	114,980	114,980
Additional paid-in capital	132,850	132,850
Deficit Accumulated	-468,367	-453,172
Total stockholders Deficit	-220,537	-205,342
TOTAL LIABILITIES AND STOCKHOLDERS DEFICIT	$15,356	$6,200

Balance_Sheets_Parenthetical

Balance Sheets (Parenthetical) (USD $)	Mar. 31, 2015	Sep. 30, 2014	Sep. 30, 2013	Jul. 09, 2010
Statement of Financial Position [Abstract]
Common stock, Par Value	$0.00	$0.00	$0.00	$0.00
Common stock, Shares Authorized	140,000,000	140,000,000	140,000,000
Common stock, Issued	114,980,000	114,980,000	77,980,000
Preferred Stock, Par Value	$0.00	$0.00	$0.00	$0.00
Preferred Stock, Shares Authorized	10,000,000	10,000,000	10,000,000	10,000,000
Preferred Stock, Issued			0

Statements_of_Operations

Statements of Operations (USD $)	3 Months Ended		6 Months Ended
	Mar. 31, 2015	Mar. 31, 2014	Mar. 31, 2015	Mar. 31, 2014
Income Statement [Abstract]
REVENUES
OPERATING EXPENSES
Stock-based compensation
Accounting and audit fees	500	2,150	2,250	2,800
Legal fees	2,111	5,086	5,190	5,411
Consulting fees		6,250		12,500
General and administrative expenses			30
TOTAL OPERATING EXPENSES	2,611	13,486	7,470	20,711
LOSS FROM OPERATIONS	-2,611	-13,486	-7,470	-20,711
OTHER INCOME (EXPENSE)
Interest expense	-4,000	-3,500	-7,725	-7,000
Financing Costs		-1,594		-1,125
TOTAL OTHER INCOME (EXPENSE)	-6,611	-5,094	-15,195	-9,625
PROVISION FOR INCOME TAXES
NET LOSS	($6,611)	($18,580)	($15,195)	($30,336)
NET LOSS PER SHARE BASIC AND DILUTED	$0	$0	$0	$0
WEIGHTED AVERAGE NUMBER OF SHARES OUTSTANDING BASIC AND DILUTED	114,980,000	114,980,000	114,980,000	114,980,000

Statements_of_Cash_Flows

Statements of Cash Flows (USD $)	6 Months Ended
	Mar. 31, 2015	Mar. 31, 2014
CASH FLOWS FROM OPERATING ACTIVITIES
Net loss for the period	($15,195)	($30,336)
Adjustments to reconcile net loss to net cash used in operating activities
Stock-based compensation
Deferred financing costs		1,125
Impairment	0	0
Gain on settlement of payables	0	0
Changes in assets and liabilities:
Decrease in prepaid expenses	0	12,500
Increase (decrease) in accrued expenses	-3,374	-3,616
Increase in accrued interest	7,725	7,000
Net Cash Used by Operating Activities	-10,844	-13,327
CASH FLOWS FROM FINANCING ACTIVITIES
Proceeds from notes payable	20,000	6,000
Net Cash Provided by Financing Activities	20,000	6,000
Net Increase (Decrease) in Cash and Cash Equivalents	9,156	-7,327
Cash and cash equivalents, beginning of period		9,327
Cash and cash equivalents, end of period	9,156	2,000
SUPPLEMENTAL CASH FLOW INFORMATION
Interest paid
Income taxes paid

NATURE_OF_BUSINESS

NATURE OF BUSINESS	6 Months Ended
	Mar. 31, 2015
Organization, Consolidation and Presentation of Financial Statements [Abstract]
NATURE OF BUSINESS	Alterola Biotech, Inc. (“Alterola” and the “Company”) is a start-up company and was incorporated in Nevada on July 21, 2008. The Company was formed for the purpose of acquiring exploration and development stage mineral properties.
	On October 1, 2008, the Company incorporated JRE Exploration Ltd, (“JRE”) a wholly owned subsidiary in Canada for the purpose of holding its Canadian mineral claims.
	On May 3, 2010, the Company changed its focus to the development of intellectual property and accordingly sold JRE to the former president. (See Note 3). In keeping with the change of business focus, on July 9, 2010, the Company changed its name to Alterola Biotech Inc.
	Effective July 9, 2010, the Board of Directors authorized a 10 for 1 forward stock split on the issued common shares. The authorized number of common shares was increased from 90,000,000 to 140,000,000 common shares with a par value of $0.001. The number of authorized Preferred shares remained unchanged at 10,000,000 with a par value of $0.001. All references in the accompanying financial statements to the number of common shares have been restated to reflect the forward stock split.

SUMMARY_OF_SIGNIFICANT_ACCOUNT

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES	6 Months Ended
	Mar. 31, 2015
Accounting Policies [Abstract]
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES	Accounting Basis
	The Company uses the accrual basis of accounting and accounting principles generally accepted in the United States of America (“GAAP” accounting).  The Company has adopted a September 30 fiscal year end.
	Basis of Presentation
	The accompanying unaudited interim financial statements of Alterola Biotech Inc. have been prepared in accordance with accounting principles generally accepted in the United States of America and the rules of the Securities and Exchange Commission (“SEC”), and should be read in conjunction with the audited financial statements and notes thereto contained in the Company’s registration statement filed with the SEC on Form 10-K. In the opinion of management, all adjustments, consisting of normal recurring adjustments, necessary for the financial statements to be not misleading have been reflected herein. The results of operations for interim periods are not necessarily indicative of the results to be expected for the full year. Notes to the financial statements which would substantially duplicate the disclosure contained in the audited financial statements for the most recent fiscal year 2014 as reported in Form 10-K, have been omitted.
	Use of Estimates
	The preparation of financial statements in conformity with generally accepted accounting principles requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date the financial statements and the reported amount of revenues and expenses during the reporting period. Actual results could differ from those estimates.
	Cash and Cash Equivalents
	For purposes of the statement of cash flows, the Company considers highly liquid financial instruments purchased with a maturity of three months or less to be cash equivalents.
	Intellectual Property
	The Company does not amortize intangible assets with indefinite useful lives, rather such assets are required to be tested for impairment at least annually or sooner whenever events or changes in circumstances indicate that the assets may be impaired. The Company amortizes its intangible assets with definite lives over their estimated useful lives and reviews these assets for impairment. The Company will amortize its acquired intangible assets with definite lives over the estimated economic life of the completed product. During the year ending September 30, 2011, the value of the intellectual property was determined to be $0 and impairment expense of $21,500 was recorded.
	Website Development Costs
	Costs incurred in developing and maintaining a website are charged to expense when incurred for the planning, content population, and administration or maintenance of the website. All development costs for the application, infrastructure, and graphics development are capitalized and subsequently reported at the lower of unamortized cost or net realizable value. Capitalized costs will be amortized using straight-line basis over two years, the estimated economic life of the completed website. As of March 31, 2015, the Company’s website was not in service; accordingly no amortization has been recorded during the periods ended March 31, 2015 and 2014.
	Fair Value of Financial Instruments
	Alterola’s financial instruments consist of cash and cash equivalents, accrued expenses, accrued interest and notes payable. The carrying amount of these financial instruments approximates fair value due either to length of maturity or interest rates that approximate prevailing market rates unless otherwise disclosed in these financial statements.
	Fair value is defined as the price that would be received upon sale of an asset or paid upon transfer of a liability in an orderly transaction between market participants at the measurement date and in the principal or most advantageous market for that asset or liability. The fair value should be calculated based on assumptions that market participants would use in pricing the asset or liability, not on assumptions specific to the entity. In addition, the fair value of liabilities should include consideration of non-performance risk including our own credit risk.
	In addition to defining fair value, the disclosure requirements around fair value establish a fair value hierarchy for valuation inputs which is expanded. The hierarchy prioritizes the inputs into three levels based on the extent to which inputs used in measuring fair value are observable in the market. Each fair value measurement is reported in one of the three levels which is determined by the lowest level input that is significant to the fair value measurement in its entirety. These levels are:
	Level 1 – inputs are based upon unadjusted quoted prices for identical instruments traded in active markets.
	Level 2 – inputs are based upon significant observable inputs other than quoted prices included in Level 1, such as quoted prices for identical or similar instruments in markets that are not active, and model-based valuation techniques for which all significant assumptions are observable in the market or can be corroborated by observable market data for substantially the full term of the assets or liabilities.
	Level 3 – inputs are generally unobservable and typically reflect management’s estimates of assumptions that market participants would use in pricing the asset or liability. The fair values are therefore determined using model-based techniques that include option pricing models, discounted cash flow models, and similar techniques.
	The carrying value of the Company’s financial assets and liabilities which consist of cash, accounts payable and accrued liabilities, and notes payable are valued using level 1 inputs. The Company believes that the recorded values approximate their fair value due to the short maturity of such instruments. Unless otherwise noted, it is management’s opinion that the Company is not exposed to significant interest, exchange or credit risks arising from these financial instruments.
	Income Taxes
	Income taxes are computed using the asset and liability method. Under the asset and liability method, deferred income tax assets and liabilities are determined based on the differences between the financial reporting and tax bases of assets and liabilities and are measured using the currently enacted tax rates and laws. A valuation allowance is provided for the amount of deferred tax assets that, based on available evidence, are not expected to be realized.
	Revenue Recognition
	The Company will recognize revenue when products are fully delivered or services have been provided and collection is reasonably assured.
	Loss Per Common Share
	Basic loss per share is calculated using the weighted-average number of common shares outstanding during each reporting period. Diluted loss per share includes potentially dilutive securities such as outstanding options and warrants, using various methods such as the treasury stock or modified treasury stock method in the determination of dilutive shares outstanding during each reporting period. The Company does not have any potentially dilutive instruments.
	Stock-Based Compensation
	Stock-based compensation is accounted for at fair value in accordance with ASC Topic 718. To date, the Company has not adopted a stock option plan and has not granted any stock options.
	During the year ended September 30, 2013, the Company issued 37,000,000 shares of common stock to its director.
	Recent Accounting Pronouncements
	Alterola does not expect the adoption of recently issued accounting pronouncements to have a significant impact on the Company’s results of operations, financial position or cash flow.

INTELLECTUAL_PROPERTY

INTELLECTUAL PROPERTY	6 Months Ended
	Mar. 31, 2015
Notes to Financial Statements
INTELLECTUAL PROPERTY	Pursuant to an Assignment Agreement dated May 3, 2010 (the “Agreement”), the Company acquired from the president of the Company a 100% undivided right in and to all intellectual property relating to certain chewing gum compositions having appetite suppressant activity. Consideration given for the acquisition was 55,000,000 Common shares of the Company with a fair value of $16,500. During the year ended September 30, 2010, the Company incurred a further $5,000 in patent application fees. During the year ended September 30, 2011, the Company determined that the value of the intellectual property was $0 and recognized impairment expense of $21,500.

ACCRUED_EXPENSES

ACCRUED EXPENSES	6 Months Ended
	Mar. 31, 2015
Payables and Accruals [Abstract]
ACCRUED EXPENSES	Accrued expenses consisted of the following at March 31, 2015 and September 30, 2014:
		31-Mar-15		30-Sep-14
	Audit fees	$	2,750	$	5,000
	Accounting		1,000		1,700
	Legal fees		25,348		25,772
	Transfer agent and filing fees		1,416		1,416
	Other		1,120		1,120
	Total Accrued Expenses	$	31,634	$	35,008

NOTES_PAYABLE

NOTES PAYABLE	6 Months Ended
	Mar. 31, 2015
Notes to Financial Statements
NOTES PAYABLE	Notes payable consisted of the following at March 31, 2015 and September 30, 2014:
		31-Mar-15		30-Sep-14
	Note payable, unsecured, bearing interest at 12% per annum, due on June 26, 2011	$	30,000	$	30,000
	Convertible note payable, unsecured, bearing interest at 12% per annum, due on July 24, 2011		50,000		50,000
	Note payable, unsecured, bearing interest at 10% per annum plus financing charge of $2,500, due on October 10, 2013		27,500		27,500
	Note payable, unsecured, bearing interest at 10% per annum plus financing charge of $1,500, due on February 13, 2014		16,500		16,500
	Note payable, unsecured, non interest bearing with finance charge of $1,500 due on March 31, 2014		6,000		6,000
	Note payable, unsecured, bearing interest at 10% per annum, due on demand		20,000		0
	Total Notes payable	$	150,000	$	130,000
	The Convertible note is convertible at the option of the holder. The number of shares of common stock into which the convertible note will be converted is determined by the Fair Market Price (“FMV”) of the common stock at the date of conversion. In the event there is no determinable market price the FMV shall be:
	a) The share price at the last private offering of the common stock, or, b) the 30 day moving average of the Common Stock in the event a public listing of the common stock has taken place.
	Notes payable in the amount of $130,000 are currently in default as of the date of issuance of these financial statements.
	Interest expense related to these notes was $7,725 and $7,000 for the periods ended March 31, 2015 and 2014, respectively.
	Financing costs are amortized over the term of the loan. As of March 31, 2015 financing costs of $nil has been expensed in the statement of operations and unamortized financing costs of $nil are deferred on the balance sheet.

CAPITAL_STOCK

CAPITAL STOCK	6 Months Ended
	Mar. 31, 2015
Equity [Abstract]
CAPITAL STOCK	The Company has 140,000,000 shares of $0.001 par value common stock authorized and 10,000,000 shares of $0.001 par value preferred stock authorized.
	On August 6, 2008, the Company issued 55,000,000 common shares to the Company’s president at $0.001 per share for total proceeds of $55,000.
	On September 22, 2008, the incumbent president resigned as both an officer and director and a new president and director was appointed. At the request of the departing president, the Company’s board of directors rescinded his share subscription for 55,000,000 common shares and repaid the subscription proceeds of $55,000.
	On September 22, 2008, the Company issued 55,000,000 common shares to the Company’s new president at $0.00095 per share for total proceeds of $52,246.
	On September 22, 2008, the Company issued 39,600,000 common shares at approximately $0.00149 per share for total proceeds of $55,740 pursuant to a private placement. On September 30, 2008, the Company issued 2,400,000 common shares at approximately $0.00149 per share for total proceeds of $3,467 pursuant to a private placement. The Company paid a commission of $5,700 for net proceeds of $53,507 for these private placements.
	On October 29, 2008, the Company issued 2,400,000 common shares at approximately $0.00119 per share for total proceeds of $2,865 pursuant to a private placement.
	On January 5, 2010, pursuant to a share subscription agreement, the Company issued 33,330,000 Common Shares at $0.0015 for aggregate proceeds of $50,000.
	On May 3, 2010, pursuant to the sale of JRE Exploration Ltd. (Note 3) the Company received 55,000,000 of its Common stock from the former Company president with a fair value of $52,246 for cancellation, as consideration for the sale of JRE, our wholly owned subsidiary.
	On November 17, 2010, the President entered into a stock cancellation agreement the Company whereby 40,000,000 common shares were returned to treasury and cancelled. In consideration the Company will issue to the President options to acquire common stock pursuant to the stock option plan which will be adopted by the Company at some time in the future.
	On December 21, 2010, the Company issued 250,000 shares at $0.20 for aggregate proceeds of $50,000.
	In February 2011, the former President returned 15,000,000 shares of common stock for voluntary cancellation.
	On July 16, 2013, the Company issued 37,000,000 shares of common stock to its director for services with a deemed value of $37,000.
	The Company has 114,980,000 and 114,980,000 shares of common stock issued and outstanding as of March 31, 2015 and September 30, 2014 respectively. There are no shares of preferred stock issued and outstanding as of March 31, 2015 and September 30, 2014.

RELATED_PARTY_TRANSACTIONS

RELATED PARTY TRANSACTIONS	6 Months Ended
	Mar. 31, 2015
Related Party Transactions [Abstract]
RELATED PARTY TRANSACTIONS	Alterola neither owns nor leases any real or personal property. An officer has provided office space without charge. There is no obligation for the officer to continue this arrangement. Such costs are immaterial to the financial statements and accordingly are not reflected herein. The officers and directors are involved in other business activities and most likely will become involved in other business activities in the future.

SUBSEQUENT_EVENTS

SUBSEQUENT EVENTS	6 Months Ended
	Mar. 31, 2015
Subsequent Events [Abstract]
SUBSEQUENT EVENTS	In accordance with ASC Topic 855-10, the Company has analyzed its operations subsequent to March 31, 2015 to the date these financial statements were issued, and has determined that it does not have any material subsequent events to disclose in these financial statements.

SUMMARY_OF_SIGNIFICANT_ACCOUNT1

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)	6 Months Ended
	Mar. 31, 2015
Accounting Policies [Abstract]
Accounting Basis	The Company uses the accrual basis of accounting and accounting principles generally accepted in the United States of America (“GAAP” accounting).  The Company has adopted a September 30 fiscal year end.
Basis of Presentation	The accompanying unaudited interim financial statements of Alterola Biotech Inc. have been prepared in accordance with accounting principles generally accepted in the United States of America and the rules of the Securities and Exchange Commission (“SEC”), and should be read in conjunction with the audited financial statements and notes thereto contained in the Company’s registration statement filed with the SEC on Form 10-K. In the opinion of management, all adjustments, consisting of normal recurring adjustments, necessary for the financial statements to be not misleading have been reflected herein. The results of operations for interim periods are not necessarily indicative of the results to be expected for the full year. Notes to the financial statements which would substantially duplicate the disclosure contained in the audited financial statements for the most recent fiscal year 2014 as reported in Form 10-K, have been omitted.
Use of Estimates	The preparation of financial statements in conformity with generally accepted accounting principles requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date the financial statements and the reported amount of revenues and expenses during the reporting period. Actual results could differ from those estimates.
Cash and Cash Equivalents	For purposes of the statement of cash flows, the Company considers highly liquid financial instruments purchased with a maturity of three months or less to be cash equivalents.
Intellectual Property	The Company does not amortize intangible assets with indefinite useful lives, rather such assets are required to be tested for impairment at least annually or sooner whenever events or changes in circumstances indicate that the assets may be impaired. The Company amortizes its intangible assets with definite lives over their estimated useful lives and reviews these assets for impairment. The Company will amortize its acquired intangible assets with definite lives over the estimated economic life of the completed product. During the year ending September 30, 2011, the value of the intellectual property was determined to be $0 and impairment expense of $21,500 was recorded.
Website Development Costs	Costs incurred in developing and maintaining a website are charged to expense when incurred for the planning, content population, and administration or maintenance of the website. All development costs for the application, infrastructure, and graphics development are capitalized and subsequently reported at the lower of unamortized cost or net realizable value. Capitalized costs will be amortized using straight-line basis over two years, the estimated economic life of the completed website. As of March 31, 2015, the Company’s website was not in service; accordingly no amortization has been recorded during the periods ended March 31, 2015 and 2014.
Fair Value of Financial Instruments	Alterola’s financial instruments consist of cash and cash equivalents, accrued expenses, accrued interest and notes payable. The carrying amount of these financial instruments approximates fair value due either to length of maturity or interest rates that approximate prevailing market rates unless otherwise disclosed in these financial statements.
	Fair value is defined as the price that would be received upon sale of an asset or paid upon transfer of a liability in an orderly transaction between market participants at the measurement date and in the principal or most advantageous market for that asset or liability. The fair value should be calculated based on assumptions that market participants would use in pricing the asset or liability, not on assumptions specific to the entity. In addition, the fair value of liabilities should include consideration of non-performance risk including our own credit risk.
	In addition to defining fair value, the disclosure requirements around fair value establish a fair value hierarchy for valuation inputs which is expanded. The hierarchy prioritizes the inputs into three levels based on the extent to which inputs used in measuring fair value are observable in the market. Each fair value measurement is reported in one of the three levels which is determined by the lowest level input that is significant to the fair value measurement in its entirety. These levels are:
	Level 1 – inputs are based upon unadjusted quoted prices for identical instruments traded in active markets.
	Level 2 – inputs are based upon significant observable inputs other than quoted prices included in Level 1, such as quoted prices for identical or similar instruments in markets that are not active, and model-based valuation techniques for which all significant assumptions are observable in the market or can be corroborated by observable market data for substantially the full term of the assets or liabilities.
	Level 3 – inputs are generally unobservable and typically reflect management’s estimates of assumptions that market participants would use in pricing the asset or liability. The fair values are therefore determined using model-based techniques that include option pricing models, discounted cash flow models, and similar techniques.
	The carrying value of the Company’s financial assets and liabilities which consist of cash, accounts payable and accrued liabilities, and notes payable are valued using level 1 inputs. The Company believes that the recorded values approximate their fair value due to the short maturity of such instruments. Unless otherwise noted, it is management’s opinion that the Company is not exposed to significant interest, exchange or credit risks arising from these financial instruments.
Income Taxes	Income taxes are computed using the asset and liability method. Under the asset and liability method, deferred income tax assets and liabilities are determined based on the differences between the financial reporting and tax bases of assets and liabilities and are measured using the currently enacted tax rates and laws. A valuation allowance is provided for the amount of deferred tax assets that, based on available evidence, are not expected to be realized.
Revenue Recognition	The Company will recognize revenue when products are fully delivered or services have been provided and collection is reasonably assured.
Loss Per Common Share	Basic loss per share is calculated using the weighted-average number of common shares outstanding during each reporting period. Diluted loss per share includes potentially dilutive securities such as outstanding options and warrants, using various methods such as the treasury stock or modified treasury stock method in the determination of dilutive shares outstanding during each reporting period. The Company does not have any potentially dilutive instruments.
Stock-Based Compensation	Stock-based compensation is accounted for at fair value in accordance with ASC Topic 718. To date, the Company has not adopted a stock option plan and has not granted any stock options.
	During the year ended September 30, 2013, the Company issued 37,000,000 shares of common stock to its director.
Recent Accounting Pronouncements	Alterola does not expect the adoption of recently issued accounting pronouncements to have a significant impact on the Company’s results of operations, financial position or cash flow.

ACCRUED_EXPENSES_Tables

ACCRUED EXPENSES (Tables)	6 Months Ended
	Mar. 31, 2015
Payables and Accruals [Abstract]
Schedule of Accrued Expenses		31-Mar-15		30-Sep-14
	Audit fees	$	2,750	$	5,000
	Accounting		1,000		1,700
	Legal fees		25,348		25,772
	Transfer agent and filing fees		1,416		1,416
	Other		1,120		1,120
	Total Accrued Expenses	$	31,634	$	35,008

NOTES_PAYABLE_Tables

NOTES PAYABLE (Tables)	6 Months Ended
	Mar. 31, 2015
Notes to Financial Statements
Schedule of Notes Payable Table		31-Mar-15		30-Sep-14
	Note payable, unsecured, bearing interest at 12% per annum, due on June 26, 2011	$	30,000	$	30,000
	Convertible note payable, unsecured, bearing interest at 12% per annum, due on July 24, 2011		50,000		50,000
	Note payable, unsecured, bearing interest at 10% per annum plus financing charge of $2,500, due on October 10, 2013		27,500		27,500
	Note payable, unsecured, bearing interest at 10% per annum plus financing charge of $1,500, due on February 13, 2014		16,500		16,500
	Note payable, unsecured, non interest bearing with finance charge of $1,500 due on March 31, 2014		6,000		6,000
	Note payable, unsecured, bearing interest at 10% per annum, due on demand		20,000		0
	Total Notes payable	$	150,000	$	130,000

NATURE_OF_BUSINESS_Details_Nar

NATURE OF BUSINESS (Details Narrative) (USD $)	0 Months Ended	6 Months Ended
	Jul. 09, 2010	Mar. 31, 2015	Sep. 30, 2014	Sep. 30, 2013
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Date of Incorporation		21-Jul-08
Forward Split Ratio	10:01
Common stock, shares authorized, pre-split	90,000,000
Common stock, shares authorized, post-split	140,000,000
Common stock, par value	$0.00	$0.00	$0.00	$0.00
Preferred stock, shares remain, unchanged	10,000,000	10,000,000	10,000,000	10,000,000
Perferred stock, par value	$0.00	$0.00	$0.00	$0.00

SUMMARY_OF_SIGNIFICANT_ACCOUNT2

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details Narrative) (USD $)	0 Months Ended	6 Months Ended
	Jul. 17, 2013	Mar. 31, 2015
Accounting Policies [Abstract]
Fiscal year end		-21
Intellectual Property, Value		$0
Impairment		$21,500
Common Stock Issued	37,000,000	37,000,000

INTELLECTUAL_PROPERTY_Details_

INTELLECTUAL PROPERTY (Details Narrative) (USD $)	0 Months Ended	6 Months Ended	0 Months Ended
	Dec. 22, 2010	Mar. 31, 2015	5-May-10
Common Stock Issued for Cash, Shares	250,000
Common Stock Issued for Cash, Value	$50,000
Patent Application Fees		5,000
Intellectual Property		0
Impairment Expense		21,500
JRE Exploration
Common Stock Issued for Cash, Shares			55,000,000
Common Stock Issued for Cash, Value			$16,500

ACCRUED_EXPENSES_Schedule_of_A

ACCRUED EXPENSES - Schedule of Accrued Expenses (Details) (USD $)	Mar. 31, 2015	Sep. 30, 2014
Payables and Accruals [Abstract]
Audit fees	$2,750	$5,000
Accounting	1,000	1,700
Legal fees	25,348	25,772
Transfer agent and filing fees	1,416	1,416
Other	1,120	1,120
Accrued expenses	$31,634	$35,008

NOTES_PAYABLE_Schedule_of_Note

NOTES PAYABLE - Schedule of Notes Payable Table (Details) (USD $)	Mar. 31, 2015	Sep. 30, 2014	Sep. 30, 2011
Notes to Financial Statements
Note payable, unsecured, bearing interest at 12% per annum, due on June 26, 2011	$30,000		$30,000
Convertible note payable, unsecured, bearing interest at 12% per annum, due on July 24, 2011	50,000		50,000
Note payable, unsecured, bearing interest at 10%, per annum plus financing charge of $2,500, due on October 10, 2013	27,500		27,500
Note payable, unsecured, bearing interest at 10%, per annum plus financing charges of $1,500, due on February 13, 2014	16,500		16,500
Note payable, unsecured, non interest bearing with finance charge of $1,500 due on March 31, 2014	6,000		6,000
Note payable, unsecured, bearing interest at 10% per annum, due on demand	20,000		0
Total Notes Payable	$150,000	$130,000	$130,000

NOTES_PAYABLE_Schedule_of_Note1

NOTES PAYABLE - Schedule of Notes Payable Table (Details) (Parenthetical) (USD $)	Mar. 31, 2015	Sep. 30, 2014
Note Payable 1
Note payable, Interest Rate	12.00%	12.00%
Note Payable 2
Convertible Note Payable, Interest Rate	12.00%	12.00%
Note Payable 3
Note payable, Interest Rate	10.00%	10.00%
Finance charge	2,500	2,500
Note Payable 4
Note payable, Interest Rate	10.00%	10.00%
Finance charge	1,500	1,500
Note Payable 5
Finance charge	1,500	1,500
Note Payable 6
Note payable, Interest Rate	10.00%	10.00%

NOTES_PAYABLE_Details_Narrativ

NOTES PAYABLE (Details Narrative) (USD $)	3 Months Ended		6 Months Ended
	Mar. 31, 2015	Mar. 31, 2014	Mar. 31, 2015	Mar. 31, 2014	Sep. 30, 2014
Notes to Financial Statements
Notes payable	$130,000		$130,000
Interest expense	4,000	3,500	7,725	7,000
Deferred financing costs

CAPITAL_STOCK_Details_Narrativ

CAPITAL STOCK (Details Narrative) (USD $)	0 Months Ended		6 Months Ended	0 Months Ended
	Jul. 17, 2013	Dec. 22, 2010	Mar. 31, 2015	5-May-10	Aug. 07, 2008	Sep. 23, 2008	Sep. 30, 2008	Oct. 30, 2008	Jan. 06, 2010	Sep. 30, 2014	Sep. 30, 2013	Feb. 01, 2011	Nov. 17, 2010	Jul. 09, 2010
Common stock, Par Value			$0.00							$0.00	$0.00			$0.00
Common stock, Shares Authorized			140,000,000							140,000,000	140,000,000
Common stock, Issued			114,980,000							114,980,000	77,980,000
Preferred Stock, Par Value			$0.00							$0.00	$0.00			$0.00
Preferred Stock, Shares Authorized			10,000,000							10,000,000	10,000,000			10,000,000
Preferred Stock, Issued											0
Common Stock Issued for Cash, Shares		250,000
Common Stock Issued for Cash, Par Value		$0.20
Common Stock Issued for Cash, Value		$50,000
Common Stock Returned to Treasury												15,000,000	40,000,000
Common Stock Issued for Services, Shares	37,000,000		37,000,000
Common Stock Issued for Services, Value	37,000
JRE Exploration
Common Stock Issued for Cash, Shares				55,000,000
Common Stock Issued for Cash, Value				16,500
Common Stock Issued for Cash, Fair Value Cancellation				52,246
Stock Issued to Old President
Common Stock Issued for Cash, Shares					55,000,000
Common Stock Issued for Cash, Par Value					$0.00
Common Stock Issued for Cash, Value					55,000
Subscription of Shares, Shares					55,000,000
Subscription of Shares, Value					55,000
Stock Issued to New President
Common Stock Issued for Cash, Shares						55,000,000
Common Stock Issued for Cash, Par Value						$0.00
Common Stock Issued for Cash, Value						52,246
Private Placement 1
Common Stock Issued for Cash, Shares						39,600,000
Common Stock Issued for Cash, Par Value						$0.00
Common Stock Issued for Cash, Value						55,740
Private Placement 2
Common Stock Issued for Cash, Shares							2,400,000
Common Stock Issued for Cash, Par Value							$0.00
Common Stock Issued for Cash, Value							3,467
Private Placement 1 and 2
Commission Cost							5,700
Net proceeds							53,507
Private Placement 3
Common Stock Issued for Cash, Shares								2,400,000
Common Stock Issued for Cash, Par Value								$0.00
Common Stock Issued for Cash, Value								2,865
Subscription Arrangement
Common Stock Issued for Cash, Shares									33,330,000
Common Stock Issued for Cash, Par Value									$0.00
Common Stock Issued for Cash, Value									$50,000